Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Fundació Sant Joan de Déu
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05394142CT.gov A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS) | — | Unknown | — | — | — |
NCT04723862CT.gov Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism? | — | Recruiting | — | — | — |
NCT04075149CT.gov Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess? | — | Unknown | — | — | — |
NCT02689843CT.gov Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS | — | Completed | — | — | — |
NCT01422759CT.gov Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess | — | Unknown | — | — | — |
NCT03068910CT.gov Hyperandrogenemia and Altered Day-night LH Pulse Patterns | — | Recruiting | — | — | — |
NCT01526616CT.gov Spironolactone Plus Metformin in Polycystic Ovary Syndrome | — | Completed | — | — | — |
NCT00842140CT.gov Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women | — | Completed | — | — | — |
NCT00004311CT.gov Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Polycystic Ovary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Spironolactone (this asset) | Fundació Sant Joan de Déu | P2 | B · 58 |
| Semaglutide | Methodist Health System | P4 | BBB |
| Human Chorionic Gonadotropin | Eman Basuni Ebrahim Mowad | P4 | BBB |
| Liraglutide | Peking University Third Hospital | P4 | BBB |
| Drospirenone | Ege University | P4 | BBB |
| Follitropin Beta | Universitair Ziekenhuis Brussel | P4 | BBB |
| Ethinyl Estradiol | Ege University | P4 | BBB |
| Glucophage | Near East University, Turkey | P4 | BBB |
| Vitamin D | Yale University | P4 | BBB |
+41 more in the Polycystic Ovary Syndrome cohort
Other indications for Spironolactone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | P4 | BB · 66 |
| Diabetic Kidney Disease | — | P4 | BB · 65 |
| Portal Hypertension | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Spironolactone in Polycystic Ovary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/spironolactone-polycystic-ovary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →